News headlines about LeMaitre Vascular (NASDAQ:LMAT) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LeMaitre Vascular earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 46.348408596231 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several equities research analysts have commented on the company. Zacks Investment Research cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, September 28th. Canaccord Genuity cut their target price on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating on the stock in a research note on Friday, October 27th. First Analysis cut LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price on the stock. in a research note on Friday, October 27th. Benchmark cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $32.20.
LeMaitre Vascular (LMAT) traded up $0.84 during midday trading on Friday, reaching $32.26. The company’s stock had a trading volume of 92,100 shares, compared to its average volume of 178,614. The company has a market cap of $605.30, a PE ratio of 40.81, a price-to-earnings-growth ratio of 2.49 and a beta of 0.55. LeMaitre Vascular has a 12-month low of $19.82 and a 12-month high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. The firm had revenue of $24.80 million for the quarter, compared to analysts’ expectations of $25.49 million. During the same quarter in the previous year, the business posted $0.17 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. sell-side analysts expect that LeMaitre Vascular will post 0.84 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 7th. Stockholders of record on Wednesday, November 22nd were paid a dividend of $0.055 per share. This represents a $0.22 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 28.57%.
In other news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the sale, the insider now owns 24,482 shares in the company, valued at approximately $786,851.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 23.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/08/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-lemaitre-vascular-lmat-stock-price.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.